Hence, use of fully human neutralising monoclonal antibodies to the growth factor TGFfβ has potential as a useful strategy for modifying conjunctival scarring. Combination therapies may also ...

It has anti-inflammatory and anti-scarring effects and contains growth factors ... bridge between the conjunctiva and the cornea. Various disorders of the surface of the eye can lead to limbal ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.